State governments use a system of open formularies known as preferred drug lists in Medicaid and other programs that purchase pharmaceuticals in order to control costs. The safety, efficacy, and cost effectiveness of new treatments are compared to existing ones, and the best drugs are included in the PDL. Federal trade policy seeks to limit this type of evidence-based pricing.
Trade, Policy and IP
PIJIP News

Professor Vicki Phillips To Be Honored By The DC Bar With The Champion of IP Award
Intellectual Property (IP) Law Community of the District of Columbia (DC) Bar will honor Professor Victoria Phillips with the esteemed Champion of IP Award. The annual Champion of IP Award celebrates an individual who has impacted IP policy, fostered innovation, and passionately advocated for intellectual property rights.
Read more
AUWCL & WIPO Sign an MOU
On April 22nd, Dean Roger Fairfax and Sheriff Saadallah, Executive Director of the World Intellectual Property Organization (WIPO) Academy, signed a Memorandum of Understanding to continue the close relationship between American University Washington College of Law's (AUWCL) Program on Information Justice & Intellectual Property (PIJIP) and WIPO.
Read more
Professor Michael Carroll Published New Paper "The Triumph of Three Big Ideas in Fair Use Jurisprudence"
Professors Carroll and Peter Jaszi, published a new paper, The Triumph of Three Big Ideas in Fair Use Jurisprudence. The article, published in the Tulane Law Review, argues that the Court’s decisions on fair use, which represent one-third of the Court’s total merits decisions, are historic.
Read more